You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | -9,498.2% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -1.0 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 139.9 | n/a |
Price / Book value | 3.8 |
Latest | Forecast | |
---|---|---|
Revenue | 12.2% | 0.0% |
PBT | 0.0% | n/a |
EPS | 0.0% | 0.0% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-06-30 | 2.36 | -4.52 | -13.87p | -1.5 | 0.0 | n/a | n/a | 0.0% |
2020-06-30 | 1.06 | -20.38 | -54.48p | -1.9 | 0.0 | n/a | n/a | 0.0% |
2021-06-30 | 0.69 | -1.85 | -1.19p | -46.9 | 0.0 | n/a | n/a | 0.0% |
2022-06-30 | 0.05 | -5.63 | 5.50p | 3.2 | 0.0 | n/a | n/a | 0.0% |
2023-06-30 | 0.06 | -5.98 | -5.50p | -3.2 | 0.0 | n/a | n/a | 0.0% |
Genedrive shares jump on NICE test recommendation Sharecast News | 03 Apr |
---|---|
Genedrive receives R&D tax credit, plans fundraise Sharecast News | 15 Mar |
Genedrive set to apply for NICE EVA funding Sharecast News | 19 Feb |
Clinical Trial Agreement | 24-Apr-24 15:36 |
---|---|
Application for Listing & Total Voting Rights | 03-Apr-24 22:40 |
NICE recommends the Genedrive CYP2C19-ID Kit | 03-Apr-24 22:39 |
Half-year Report | 28-Mar-24 07:01 |
Application for Listing & Total Voting Rights | 19-Mar-24 15:53 |